4-(1,3-bis(4-methoxybenzyl)hexahydropyrimidin-2-yl)-N,N-dimethylaniline | 97013-79-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(1,3-bis(4-methoxybenzyl)hexahydropyrimidin-2-yl)-N,N-dimethylaniline
• 英文别名: 4-[1,3-bis-(4-methoxy-benzyl)-hexahydro-pyrimidin-2-yl]-N,N-dimethyl-aniline；1,3-Bis-(4-methoxy-benzyl)-2-(4-dimethylamino-phenyl)-hexahydropyrimidin；4-[1,3-bis[(4-methoxyphenyl)methyl]hexahydropyrimidin-2-yl]-N,N-dimethyl-aniline；4-[1,3-bis[(4-methoxyphenyl)methyl]-1,3-diazinan-2-yl]-N,N-dimethylaniline
• CAS: 97013-79-1
• 化学式: C₂₈H₃₅N₃O₂
• 分子量: 445.605
• InChiKey: XFXOUGQYXWAHCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N,N′-bis[(4-methoxyphenyl)methlylidene]propane-1,3-diamine 在 sodium tetrahydroborate 作用下， 以 二氯甲烷 为溶剂， 生成 4-(1,3-bis(4-methoxybenzyl)hexahydropyrimidin-2-yl)-N,N-dimethylaniline
  参考文献：
  名称：

  Synthesis, Cytotoxicity, Antibacterial and Antileishmanial Activities of Imidazolidine and Hexahydropyrimidine Derivatives

  摘要：

  本文介绍了咪唑烷和六氢嘧啶衍生物的合成及其对细菌（大肠杆菌、金黄色葡萄球菌和结核分枝杆菌）和利什曼原虫的体外生物活性。在测试的 16 种杂环衍生物中，没有一种对哺乳动物细胞具有细胞毒性。这些化合物具有明显的杀菌作用和杀利什曼原虫活性。化合物 4a 和 4c 分别对金黄色葡萄球菌和大肠杆菌具有活性。化合物 3a-3f、4h 和 4i 对结核杆菌有很好的疗效，其 MIC 值介于 12.5 至 25.0 μg/mL 之间，与用于治疗结核病的 "一线和二线 "药物相当。化合物 4a、4c 和 4e 对大肠杆菌具有活性。单晶 X 射线衍射对其中三种化合物进行了结构表征。

  DOI：

  10.2174/1573406411309030005

文献信息

• Synthesis, Cytotoxicity, Antibacterial and Antileishmanial Activities of Imidazolidine and Hexahydropyrimidine Derivatives
  作者：Gustavo S. G. de Carvalho、Rafael M. P. Dias、Fernando R. Pavan、Clarice Q. F. Leite、Vania L. Silva、Claudio G. Diniz、Daniela T. S. de Paula、Elaine S. Coimbra、Pascal Retailleau、Adilson D. da Silva

  DOI：10.2174/1573406411309030005

  日期：2013.2.1

  This paper describes the synthesis and in vitro biological activities of imidazolidine and hexahydropyrimidine derivatives against bacteria (Escherichia coli, Staphylococcus aureus and Mycobacterium tuberculosis) and Leishmania protozoa. Out of sixteen heterocyclic derivatives tested, none were cytotoxic against mammalian cells. The compounds showed significant bacterial effects and leishmanicidal activity. Compounds 4a and 4c were active against S. aureus and E. coli, respectively. Compounds 3a-3f, 4h and 4i presented promising results against M. tuberculosis, with MIC values ranging from 12.5 to 25.0 μg/mL, comparable to the “first and second line” drugs used to treat tuberculosis. Compounds 4a, 4c and 4e were active against L major. Three of them were structurally characterized by single-crystal X-ray diffraction.

  本文介绍了咪唑烷和六氢嘧啶衍生物的合成及其对细菌（大肠杆菌、金黄色葡萄球菌和结核分枝杆菌）和利什曼原虫的体外生物活性。在测试的 16 种杂环衍生物中，没有一种对哺乳动物细胞具有细胞毒性。这些化合物具有明显的杀菌作用和杀利什曼原虫活性。化合物 4a 和 4c 分别对金黄色葡萄球菌和大肠杆菌具有活性。化合物 3a-3f、4h 和 4i 对结核杆菌有很好的疗效，其 MIC 值介于 12.5 至 25.0 μg/mL 之间，与用于治疗结核病的 "一线和二线 "药物相当。化合物 4a、4c 和 4e 对大肠杆菌具有活性。单晶 X 射线衍射对其中三种化合物进行了结构表征。
• Khan; Gupta, Pharmazie, 2002, vol. 57, # 6, p. 377 - 383
  作者：Khan、Gupta

  DOI：——

  日期：——
• Synthesis and evaluation of hexahydropyrimidines and diamines as novel hepatitis C virus inhibitors
  作者：Jong Yeon Hwang、Hee-Young Kim、Suyeon Jo、Eunjung Park、Jihyun Choi、Sunju Kong、Dong-Sik Park、Ja Myung Heo、Jong Seok Lee、Yoonae Ko、Inhee Choi、Jonathan Cechetto、Jaeseung Kim、Jinhwa Lee、Zaesung No、Marc Peter Windisch

  DOI：10.1016/j.ejmech.2013.09.055

  日期：2013.12

  In order to identify novel anti-hepatitis C virus (HCV) agents we devised cell-based strategies and screened phenotypically small molecule chemical libraries with infectious HCV particles, and identified a hit compound (1) containing a hexahydropyrimidine (HHP) core. During our cell-based SAR study, we observed a conversion of HHP 1 into a linear diamine (6), which is the active component in inhibiting HCV and exhibited comparable antiviral activity to the cyclic HHP I. In addition, we engaged into the biological characterization of HHP and demonstrated that HHP does not interfere with HCV RNA replication, but with entry and release of viral particles. Here we report the results of the preliminary SAR and mechanism of action studies with HHP. (C) 2013 Elsevier Masson SAS. All rights reserved.